Evaluation of the Efficacy of Xyloglucan, Pea Protein and Opuntia ficus-indica Extract in a Preclinical Model of Psoriasis.

Publisher: MDPI Country of Publication: Switzerland NLM ID: 101092791 Publication Model: Electronic Cited Medium: Internet ISSN: 1422-0067 (Electronic) Linking ISSN: 14220067 NLM ISO Abbreviation: Int J Mol Sci Subsets: MEDLINE

Original Publication: Basel, Switzerland : MDPI, [2000-

Opuntia* ; Pea Proteins* ; Psoriasis* ; Dermatitis* ; Skin Diseases*; Mice ; Animals ; Staphylococcus aureus ; Dexamethasone

Psoriasis is a chronic inflammatory skin disease characterized by epidermal gene abnormalities, epidermal barrier defects and inflammation. Corticosteroids are considered to be standard treatments, but often come with side effects and lose efficacy with long-term use. Alternative treatments targeting the epidermal barrier defect are needed to manage the disease. Film-forming substances such as xyloglucan, pea protein and Opuntia ficus-indica extract (XPO) have generated interest for their ability to restore skin barrier integrity and may pose an alternative approach to disease management. Thus, the aim of this two-part study was to evaluate the barrier-protective properties of a topical cream containing XPO on the membrane permeability of keratinocytes exposed to inflammatory conditions and compare its efficacy to dexamethasone (DXM) in an in vivo model of psoriasis-like dermatitis. XPO treatment significantly reduced S. aureus adhesion, subsequent skin invasion and restored epithelial barrier function in keratinocytes. Furthermore, the treatment restored the integrity of keratinocytes, reducing tissue damage. In mice with psoriasis-like dermatitis, XPO significantly reduced erythema, inflammatory markers and epidermal thickening with a superior efficacy to dexamethasone. Given the promising results, XPO may represent a novel steroid-sparing therapeutic for epidermal-related diseases such as psoriasis, thanks to its ability to preserve skin barrier function and integrity.

Biomed Pharmacother. 2020 Jan;121:109615. (PMID: 31707343)
Can Fam Physician. 2005 Apr;51:519-25. (PMID: 15856971)
Sci Rep. 2018 Jun 28;8(1):9573. (PMID: 29955077)
Future Microbiol. 2016 May;11:651-8. (PMID: 27022857)
J Invest Dermatol. 2013 Feb;133(2):377-85. (PMID: 23014338)
Pharmaceutics. 2020 Aug 20;12(9):. (PMID: 32825447)
Front Cell Infect Microbiol. 2019 Feb 04;9:7. (PMID: 30778377)
Int J Biometeorol. 2013 Jan;57(1):137-43. (PMID: 22434485)
Dermatol Ther. 2021 Jan;34(1):e14538. (PMID: 33188584)
Int J Mol Sci. 2020 May 07;21(9):. (PMID: 32392785)
Carbohydr Polym. 2018 Jan 1;179:262-272. (PMID: 29111050)
Cell Mol Immunol. 2012 Jul;9(4):302-9. (PMID: 22705915)
Nutrients. 2022 Mar 25;14(7):. (PMID: 35405982)
J Invest Dermatol. 2005 Aug;125(2):183-200. (PMID: 16098026)
Arch Dermatol Res. 2013 Aug;305(6):501-12. (PMID: 23775225)
Methods Mol Biol. 2014;1195:33-41. (PMID: 24155234)
Int J Mol Sci. 2020 Jul 17;21(14):. (PMID: 32708987)
Future Microbiol. 2017 Jun;12:721-731. (PMID: 28345957)
Fitoterapia. 2001 Feb;72(2):165-7. (PMID: 11223226)
Am J Infect Control. 2012 Dec;40(10):973-8. (PMID: 23017546)
Toxicol Pathol. 2016 Jun;44(4):536-44. (PMID: 26992887)
Toxins (Basel). 2017 Dec 27;10(1):. (PMID: 29280945)
Genomics Proteomics Bioinformatics. 2015 Aug;13(4):224-33. (PMID: 26362816)
Expert Rev Gastroenterol Hepatol. 2018 Jan;12(1):83-90. (PMID: 28946778)
Br J Dermatol. 2018 Jul;179(1):173-181. (PMID: 29328510)
Front Microbiol. 2022 Jan 04;12:753518. (PMID: 35058892)
Front Vet Sci. 2022 Jan 28;8:791371. (PMID: 35155646)
Carbohydr Polym. 2017 Feb 10;157:128-136. (PMID: 27987833)
J Immunol. 2010 Mar 24;184(9):5263-5270. (PMID: 20335534)
Postgrad Med J. 2007 Nov;83(985):690-7. (PMID: 17989268)
Infect Immun. 2004 Oct;72(10):5668-75. (PMID: 15385465)
Appl Environ Microbiol. 2005 Jun;71(6):2880-7. (PMID: 15932981)
Indian Dermatol Online J. 2019 May-Jun;10(3):267-271. (PMID: 31149569)
Exp Dermatol. 2005 Oct;14(10):719-26. (PMID: 16176279)
J Immunol. 2011 Jul 1;187(1):490-500. (PMID: 21606249)
Fluids Barriers CNS. 2013 Jan 10;10(1):5. (PMID: 23305242)
Mol Nutr Food Res. 2015 Apr;59(4):807-19. (PMID: 25626675)
Exp Biol Med (Maywood). 2017 Jun;242(11):1158-1169. (PMID: 28585891)
Microb Physiol. 2020;30(1-6):50-60. (PMID: 33070135)
Trends Genet. 2010 Sep;26(9):415-23. (PMID: 20692714)
Int J Biol Macromol. 2015 Nov;81:483-90. (PMID: 26306411)
Int J Mol Sci. 2018 Feb 27;19(3):. (PMID: 29495535)
J Lab Autom. 2015 Apr;20(2):107-26. (PMID: 25586998)
Annu Rev Immunol. 2014;32:227-55. (PMID: 24655295)
J Vis Exp. 2019 Aug 19;(150):. (PMID: 31475964)
Biophys J. 1996 Nov;71(5):2692-700. (PMID: 8913606)
Eur J Dermatol. 2009 May-Jun;19(3):238-42. (PMID: 19286488)
Int J Mol Sci. 2020 May 19;21(10):. (PMID: 32438777)
Int J Mol Sci. 2019 Mar 25;20(6):. (PMID: 30934587)
Indian Dermatol Online J. 2017 Jul-Aug;8(4):235-245. (PMID: 28761838)
J Invest Dermatol. 2014 Nov;134(11):2843-2846. (PMID: 24780930)
Evid Based Complement Alternat Med. 2018 Jan 24;2018:7931031. (PMID: 29619073)
Cell Mol Life Sci. 2021 Mar;78(6):2709-2727. (PMID: 33386888)
Wound Repair Regen. 2009 Sep-Oct;17(5):730-8. (PMID: 19769725)
Arch Dermatol Res. 1988;280(4):189-93. (PMID: 3233011)

Keywords: Opuntia ficus-indica extract; barrier function; pea protein; psoriasis; xyloglucan

37294-28-3 (xyloglucan)
0 (Pea Proteins)
7S5I7G3JQL (Dexamethasone)

Date Created: 20230225 Date Completed: 20230228 Latest Revision: 20230301

20231215

PMC9966091

10.3390/ijms24043122

36834534